Profile data is unavailable for this security.
About the company
Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients (API). It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopaedic and Gynaecology. Products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its India Formulations. Its subsidiaries include Alembic Pharmaceuticals Inc., Alembic Global Holding SA and others.
- Revenue in INR (TTM)62.29bn
- Net income in INR6.16bn
- Incorporated2010
- Employees14.59k
- LocationAlembic Pharmaceuticals LtdAlembic RoadVADODARA 390003IndiaIND
- Phone+91 2 652282550
- Fax+91 2 652281508
- Websitehttps://alembicpharmaceuticals.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caplin Point Laboratories Ltd | 16.94bn | 4.57bn | 97.99bn | 777.00 | 21.54 | 4.23 | 19.03 | 5.78 | 59.90 | 59.90 | 222.01 | 304.93 | 0.6931 | 2.22 | 3.62 | -- | 18.88 | 19.83 | 21.80 | 22.82 | 57.25 | 53.99 | 27.24 | 25.39 | 4.63 | 976.47 | 0.0008 | 7.86 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 2.59 |
| Granules India Ltd | 45.06bn | 4.05bn | 101.43bn | 3.65k | 25.01 | 3.14 | 16.56 | 2.25 | 16.73 | 16.73 | 186.06 | 133.08 | 0.8645 | 1.65 | 4.66 | -- | 7.78 | 10.68 | 12.41 | 16.18 | 55.15 | 51.39 | 8.99 | 11.82 | 0.7706 | 6.13 | 0.2896 | 7.84 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Glenmark Life Sciences Ltd | 22.83bn | 4.71bn | 102.46bn | 1.82k | 21.79 | 4.39 | 19.54 | 4.49 | 38.38 | 38.38 | 186.08 | 190.35 | 0.8224 | 1.58 | 2.90 | -- | 16.96 | 18.28 | 20.43 | 30.03 | 56.11 | 53.40 | 20.62 | 20.23 | 2.85 | 401.55 | 0.0073 | -- | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Jubilant Pharmova Ltd | 67.03bn | 771.00m | 108.95bn | 1.03k | 141.87 | 2.01 | 23.97 | 1.63 | 4.85 | 4.85 | 421.25 | 343.16 | 0.5904 | 1.60 | 7.14 | -- | 0.6404 | 2.96 | 0.7627 | 3.55 | 68.06 | 69.37 | 1.08 | 5.13 | 1.37 | 2.09 | 0.4033 | 24.69 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
| Eris Lifesciences Ltd | 20.09bn | 3.92bn | 124.64bn | 3.55k | 31.83 | 4.82 | 21.50 | 6.20 | 28.78 | 28.78 | 147.52 | 190.12 | 0.375 | 2.37 | 5.62 | -- | 7.41 | 13.42 | 11.22 | 16.80 | 81.08 | 80.29 | 19.76 | 24.96 | 0.8345 | 5.80 | 0.4633 | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
| Concord Biotech Ltd | 10.17bn | 3.08bn | 153.11bn | -- | 49.71 | 10.03 | 42.33 | 15.06 | 29.44 | 29.44 | 97.17 | 145.93 | -- | -- | -- | -- | -- | -- | -- | -- | 77.46 | -- | 30.30 | -- | 4.84 | -- | 0.0063 | -- | 19.20 | -- | 28.33 | -- | -- | -- |
| Astrazeneca Pharma India Ltd | 12.96bn | 1.62bn | 154.48bn | 947.00 | 95.65 | 21.70 | 87.55 | 11.92 | 64.60 | 64.60 | 518.18 | 284.77 | 1.26 | 2.84 | 9.94 | -- | 15.66 | 11.78 | 24.44 | 19.62 | 54.11 | 56.40 | 12.47 | 10.27 | 1.97 | 141.18 | 0.0064 | 27.16 | 29.17 | 12.21 | 62.66 | 24.29 | -10.45 | -- |
| Suven Pharmaceuticals Ltd | 10.51bn | 3.00bn | 157.14bn | 1.17k | 52.27 | 7.66 | 44.30 | 14.95 | 11.81 | 11.81 | 41.36 | 80.56 | 0.4983 | 1.64 | 8.60 | -- | 14.23 | 23.17 | 15.19 | 26.20 | 57.59 | 58.56 | 28.56 | 33.21 | 9.65 | 66.88 | 0.0307 | -- | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
| Piramal Enterprises Ltd | 80.27bn | -16.84bn | 177.69bn | 12.22k | -- | 0.6691 | -- | 2.21 | -76.51 | -76.51 | 345.53 | 1,187.94 | 0.0965 | -- | 497.33 | -- | -2.02 | 2.57 | -2.05 | 3.16 | 45.17 | 81.98 | -20.97 | 21.59 | -- | -0.0035 | 0.6686 | 26.39 | -3.80 | -7.55 | -116.89 | -- | 12.91 | -18.22 |
| Natco Pharma Ltd. | 39.99bn | 13.88bn | 178.69bn | 3.98k | 12.91 | 3.05 | 11.34 | 4.47 | 77.30 | 77.30 | 222.76 | 326.99 | 0.6366 | 0.9929 | 3.91 | -- | 22.10 | 12.33 | 25.46 | 14.25 | 82.08 | 76.47 | 34.72 | 25.16 | 3.42 | 81.49 | 0.0596 | -- | 47.72 | 13.81 | 94.09 | 16.59 | -5.76 | -- |
| Alembic Pharmaceuticals Ltd | 62.29bn | 6.16bn | 181.45bn | 14.59k | 29.45 | 3.77 | 20.40 | 2.91 | 31.34 | 31.34 | 317.00 | 245.12 | 0.9865 | 1.10 | 6.01 | -- | 9.77 | 10.82 | 12.94 | 14.38 | 72.46 | 67.67 | 9.90 | 12.58 | 0.9863 | 11.76 | 0.0963 | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Piramal Pharma Ltd | 81.71bn | 178.20m | 195.55bn | 6.30k | 2,467.50 | 2.48 | 25.78 | 2.39 | 0.06 | 0.06 | 65.09 | 59.80 | 0.5478 | 1.53 | 4.15 | -- | 0.1195 | -- | 0.1648 | -- | 63.85 | -- | 0.2181 | -- | 0.7527 | 6.74 | 0.3732 | -- | 15.39 | -- | 109.56 | -- | -- | -- |
| Sanofi India Ltd | 28.47bn | 5.49bn | 198.69bn | 2.17k | 36.19 | -- | 33.73 | 6.98 | 238.42 | 238.42 | 1,236.19 | -- | -- | -- | -- | 13,095,680.00 | -- | 22.42 | -- | 30.21 | 57.68 | 55.52 | 19.29 | 21.03 | -- | 442.82 | -- | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Pfizer Ltd | 21.93bn | 5.51bn | 210.89bn | 1.70k | 38.25 | 5.87 | 34.37 | 9.62 | 120.52 | 120.52 | 479.40 | 785.95 | 0.533 | 1.86 | 12.93 | -- | 13.40 | 14.22 | 15.69 | 17.71 | 63.86 | 61.79 | 25.14 | 24.05 | 4.27 | 37.18 | 0.0256 | 23.74 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
| Laurus Labs Ltd | 50.41bn | 1.61bn | 225.87bn | 5.75k | 141.06 | 5.49 | 40.86 | 4.48 | 2.97 | 2.97 | 93.27 | 76.27 | 0.6282 | 1.38 | 3.11 | -- | 2.10 | 10.13 | 3.21 | 16.47 | 51.75 | 49.35 | 3.34 | 12.83 | 0.6393 | 2.15 | 0.3851 | -- | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| Syngene International Ltd | 34.89bn | 5.10bn | 269.71bn | 6.85k | 53.00 | 6.33 | 28.82 | 7.73 | 12.68 | 12.68 | 86.73 | 106.24 | 0.5823 | 3.26 | 7.19 | -- | 8.51 | 8.62 | 10.57 | 11.43 | 73.34 | 71.65 | 14.62 | 16.22 | 1.50 | 6.26 | 0.1154 | -- | 9.26 | 13.83 | 9.82 | 8.99 | -2.62 | 20.11 |
Data as of May 31 2024. Currency figures normalised to Alembic Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
13.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2023 | 8.50m | 4.33% |
| DSP Asset Managers Pvt. Ltd.as of 15 May 2024 | 7.69m | 3.91% |
| Kotak Mahindra Asset Management Co. Ltd.as of 30 Apr 2024 | 3.47m | 1.76% |
| The Vanguard Group, Inc.as of 09 May 2024 | 1.82m | 0.93% |
| Axis Asset Management Co. Ltd.as of 30 Apr 2024 | 1.40m | 0.71% |
| Union Asset Management Co. Pvt Ltd.as of 30 Apr 2024 | 1.02m | 0.52% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 983.91k | 0.50% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 30 Apr 2024 | 755.96k | 0.39% |
| BlackRock Fund Advisorsas of 09 May 2024 | 751.40k | 0.38% |
| Mahindra Manulife Investment Management Pvt Ltd.as of 30 Apr 2024 | 406.00k | 0.21% |
More ▼
Data from 31 Mar 2024 - 15 May 2024Source: FactSet Research Systems Inc.
